Contact
searchSearch
HMP Global
Login

Urothelial Carcinoma Excellence Forum

Urothelial Carcinoma
Excellence Forum
Leaders in the field sharing authoritative insights and institutional best practices.

Muneeb Alam
Videos
Defining the Features of Urothelial Carcinoma at ASCO GU 2024
02/21/2024
Syed Muneeb Alam, MD, from Memorial Sloan Kettering Cancer Center, shares some details about the abstract he presented at ASCO GU 2024 on the definition, diagnosis, and new technologies available for physicians treating patients with...
Syed Muneeb Alam, MD, from Memorial Sloan Kettering Cancer Center, shares some details about the abstract he presented at ASCO GU 2024 on the definition, diagnosis, and new technologies available for physicians treating patients with...
Syed Muneeb Alam, MD, from...
02/21/2024
Journal of Clinical Pathways
Andrea Apolo, MD, National Cancer Institute
Conference Coverage
Adjuvant Pembrolizumab New Therapeutic Option For High-Risk Muscle-Invasive Bladder Cancer
02/05/2024
At the 2024 ASCO GU Cancers Symposium, Andrea Apolo, MD, shared insights from the phase 3 AMBASSADOR Alliance AO31501 study, looking at adjuvant pembrolizumab for patients with muscle-invasive bladder cancer at a high risk for recurrence.
At the 2024 ASCO GU Cancers Symposium, Andrea Apolo, MD, shared insights from the phase 3 AMBASSADOR Alliance AO31501 study, looking at adjuvant pembrolizumab for patients with muscle-invasive bladder cancer at a high risk for recurrence.
At the 2024 ASCO GU Cancers...
02/05/2024
Oncology
David Aggen, MD, PhD
Conference Coverage
HER2 and PD-L1 Immunohistochemistry Expression Among Patients With Advanced Bladder Cancer
01/30/2024
David Aggen, MD, shares insights from a retrospective analysis done to evaluate the association between HER2 mutation/amplification, HER2, and PD-L1 immunohistochemistry expression, and associations with clinical outcomes for advanced bladder...
David Aggen, MD, shares insights from a retrospective analysis done to evaluate the association between HER2 mutation/amplification, HER2, and PD-L1 immunohistochemistry expression, and associations with clinical outcomes for advanced bladder...
David Aggen, MD, shares insights...
01/30/2024
Oncology
Thomas Powles, MBBS, MD
Conference Coverage
Belzutifan Improves Quality of Life Among Patients With Advanced Clear Cell Renal Cell Carcinoma
01/27/2024
Thomas Powles, MBBS, MD, discusses results from the phase 3 LITESPARK-005 study which compared patient-reported outcomes among patients treated with belzutifan and everolimus for advanced/metastatic clear cell renal cell carcinoma.
Thomas Powles, MBBS, MD, discusses results from the phase 3 LITESPARK-005 study which compared patient-reported outcomes among patients treated with belzutifan and everolimus for advanced/metastatic clear cell renal cell carcinoma.
Thomas Powles, MBBS, MD,...
01/27/2024
Oncology
Toni Choueiri, MD.
Videos
KEYNOTE-564 Study of Adjuvant Pembrolizumab vs Placebo for the Treatment of Clear Cell Renal Cell Carcinoma
01/27/2024
Toni Choueiri, MD, gives a summary of the findings from the phase 3 KEYNOTE-564 study, which analyzed the overall survival of pembrolizumab for the treatment of clear renal cell carcinoma.
Toni Choueiri, MD, gives a summary of the findings from the phase 3 KEYNOTE-564 study, which analyzed the overall survival of pembrolizumab for the treatment of clear renal cell carcinoma.
Toni Choueiri, MD, gives a...
01/27/2024
Journal of Clinical Pathways
Michiel van der Heijden, MD 
Conference Coverage
Enfortumab Vedotin Plus Pembrolizumab Potential New Standard of Care for Advanced Urothelial Carcinoma in the First-Line Setting
01/26/2024
Michiel van der Heijden, MD, discusses the subgroup analyses of the phase 3 EV-302 study, evaluating enfortumab vedotin plus pembrolizumab among patients with locally advanced or metastatic urothelial carcinoma in the first-line setting.
Michiel van der Heijden, MD, discusses the subgroup analyses of the phase 3 EV-302 study, evaluating enfortumab vedotin plus pembrolizumab among patients with locally advanced or metastatic urothelial carcinoma in the first-line setting.
Michiel van der Heijden, MD,...
01/26/2024
Oncology
Dr Eun-mi Yu
Videos
The Impact of Upper Tract Urothelial Cancer Treatments Based on the National Cancer Database’s Findings
08/29/2023
Eun-mi Yu, MD, speaks on her research on upper tract urothelial cancer treatments that was presented at the 2023 ASCO Annual Meeting.
Eun-mi Yu, MD, speaks on her research on upper tract urothelial cancer treatments that was presented at the 2023 ASCO Annual Meeting.
Eun-mi Yu, MD, speaks on her...
08/29/2023
Journal of Clinical Pathways
Dr Rana McKay.
ENGAGING EXPERTS
Antitumor Activity of Enfortumab Vedotin in Locally Advanced or Metastatic Urothelial Cancer
06/19/2023
Dr Rana McKay, a genitourinary medical oncologist at the University of California San Diego, discusses the results of EV-103 cohort K, which assessed the efficacy of enfortumab vedotin monotherapy or in combination with pembrolizumab in...
Dr Rana McKay, a genitourinary medical oncologist at the University of California San Diego, discusses the results of EV-103 cohort K, which assessed the efficacy of enfortumab vedotin monotherapy or in combination with pembrolizumab in...
Dr Rana McKay, a genitourinary...
06/19/2023
Journal of Clinical Pathways
Barragan-Carrillo, MD
Conference Coverage
Impact of Race and Payor Status on Nephrectomy Procedure Type in Patients With Renal Cell Carcinoma
06/08/2023
In an interview with the Journal of Clinical Pathways at the ASCO 2023 Annual Meeting, Regina Barragán-Carrillo, MD, discusses her study on the influence of race and payor status on the treatment patterns of partial versus radical nephrectomy...
In an interview with the Journal of Clinical Pathways at the ASCO 2023 Annual Meeting, Regina Barragán-Carrillo, MD, discusses her study on the influence of race and payor status on the treatment patterns of partial versus radical nephrectomy...
In an interview with the Journal...
06/08/2023
Journal of Clinical Pathways
Dr Rana McKay, medical oncologist at the University of California in San Diego.
Videos
Characterization of FOLH1 Expression in Renal Cell Carcinoma
04/11/2023
Dr Rana McKay, MD, Associate Professor of Medicine at the University of California San Diego, discusses the findings from her study, "Characterization of FOLH1 expression in renal cell carcinoma."
Dr Rana McKay, MD, Associate Professor of Medicine at the University of California San Diego, discusses the findings from her study, "Characterization of FOLH1 expression in renal cell carcinoma."
Dr Rana McKay, MD, Associate...
04/11/2023
Journal of Clinical Pathways
Nov-Dec 2024 Issue Cover

Current Issue

December 2024
Volume 10
Issue 6
Current Issue
Issue Archive

Special Reports

JCP Special Report
Recommendations for Creating an Oncology Clinical Pathways Framework Tool Based on Payer, Provider, and Patient Priorities: Findings From the 2021 Care Pathways Working Group
05/20/2022
The Journal of Clinical Pathways convened the 2021 Care Pathways Working Group to identify and reconcile the different pathway drivers for each stakeholder now and five years into the future, creating a framework tool based on oncology care...
The Journal of Clinical Pathways convened the 2021 Care Pathways Working Group to identify and reconcile the different pathway drivers for each stakeholder now and five years into the future, creating a framework tool based on oncology care...
The Journal of Clinical Pathways...
05/20/2022
Journal of Clinical Pathways

Subscribe

Journal of Clinical Pathways Newsletter

Recent Stories

Muneeb Alam
Videos
Defining the Features of Urothelial Carcinoma at ASCO GU 2024
02/21/2024
Syed Muneeb Alam, MD, from Memorial Sloan Kettering Cancer Center, shares some details about the abstract he presented at ASCO GU 2024 on the definition, diagnosis, and new technologies available for physicians treating patients with...
Syed Muneeb Alam, MD, from Memorial Sloan Kettering Cancer Center, shares some details about the abstract he presented at ASCO GU 2024 on the definition, diagnosis, and new technologies available for physicians treating patients with...
Syed Muneeb Alam, MD, from...
02/21/2024
Journal of Clinical Pathways
Andrea Apolo, MD, National Cancer Institute
Conference Coverage
Adjuvant Pembrolizumab New Therapeutic Option For High-Risk Muscle-Invasive Bladder Cancer
02/05/2024
At the 2024 ASCO GU Cancers Symposium, Andrea Apolo, MD, shared insights from the phase 3 AMBASSADOR Alliance AO31501 study, looking at adjuvant pembrolizumab for patients with muscle-invasive bladder cancer at a high risk for recurrence.
At the 2024 ASCO GU Cancers Symposium, Andrea Apolo, MD, shared insights from the phase 3 AMBASSADOR Alliance AO31501 study, looking at adjuvant pembrolizumab for patients with muscle-invasive bladder cancer at a high risk for recurrence.
At the 2024 ASCO GU Cancers...
02/05/2024
Oncology
David Aggen, MD, PhD
Conference Coverage
HER2 and PD-L1 Immunohistochemistry Expression Among Patients With Advanced Bladder Cancer
01/30/2024
David Aggen, MD, shares insights from a retrospective analysis done to evaluate the association between HER2 mutation/amplification, HER2, and PD-L1 immunohistochemistry expression, and associations with clinical outcomes for advanced bladder...
David Aggen, MD, shares insights from a retrospective analysis done to evaluate the association between HER2 mutation/amplification, HER2, and PD-L1 immunohistochemistry expression, and associations with clinical outcomes for advanced bladder...
David Aggen, MD, shares insights...
01/30/2024
Oncology
Thomas Powles, MBBS, MD
Conference Coverage
Belzutifan Improves Quality of Life Among Patients With Advanced Clear Cell Renal Cell Carcinoma
01/27/2024
Thomas Powles, MBBS, MD, discusses results from the phase 3 LITESPARK-005 study which compared patient-reported outcomes among patients treated with belzutifan and everolimus for advanced/metastatic clear cell renal cell carcinoma.
Thomas Powles, MBBS, MD, discusses results from the phase 3 LITESPARK-005 study which compared patient-reported outcomes among patients treated with belzutifan and everolimus for advanced/metastatic clear cell renal cell carcinoma.
Thomas Powles, MBBS, MD,...
01/27/2024
Oncology
Toni Choueiri, MD.
Videos
KEYNOTE-564 Study of Adjuvant Pembrolizumab vs Placebo for the Treatment of Clear Cell Renal Cell Carcinoma
01/27/2024
Toni Choueiri, MD, gives a summary of the findings from the phase 3 KEYNOTE-564 study, which analyzed the overall survival of pembrolizumab for the treatment of clear renal cell carcinoma.
Toni Choueiri, MD, gives a summary of the findings from the phase 3 KEYNOTE-564 study, which analyzed the overall survival of pembrolizumab for the treatment of clear renal cell carcinoma.
Toni Choueiri, MD, gives a...
01/27/2024
Journal of Clinical Pathways

Specialties

Events

Year Round Education

HMP Global Products

HMP Education Logo
HMP Omnimedia Logo
HMP Europe Logo
© 2025 HMP Global. All Rights Reserved.
Cookie Policy Privacy Policy Term of Use